O	0	10	Expression	Expression	NN	B-NP
O	11	14	and	and	CC	I-NP
O	15	27	purification	purification	NN	I-NP
O	28	30	of	of	IN	B-PP
O	31	34	the	the	DT	B-NP
O	35	44	catalytic	catalytic	JJ	I-NP
O	45	51	domain	domain	NN	I-NP
O	52	54	of	of	IN	B-PP
O	55	60	human	human	JJ	B-NP
O	61	69	vascular	vascular	JJ	I-NP
O	70	81	endothelial	endothelial	JJ	I-NP
O	82	88	growth	growth	NN	I-NP
O	89	95	factor	factor	NN	I-NP
O	96	104	receptor	receptor	NN	I-NP
O	105	106	2	2	CD	B-NP
O	107	110	for	for	IN	B-PP
O	111	120	inhibitor	inhibitor	NN	B-NP
O	121	130	screening	screening	NN	I-NP
O	130	131	.	.	.	O

O	132	140	Vascular	Vascular	JJ	B-NP
O	141	152	endothelial	endothelial	JJ	I-NP
O	153	159	growth	growth	NN	I-NP
O	160	166	factor	factor	NN	I-NP
O	167	168	(	(	(	O
O	168	172	VEGF	VEGF	NN	B-NP
O	172	173	)	)	)	O
O	173	174	,	,	,	O
O	175	177	an	an	DT	B-NP
B-Cell	178	189	endothelial	endothelial	JJ	I-NP
I-Cell	190	194	cell	cell	NN	I-NP
O	194	195	-	-	HYPH	B-NP
O	195	203	specific	specific	JJ	I-NP
O	204	211	mitogen	mitogen	NN	I-NP
O	211	212	,	,	,	O
O	213	216	can	can	MD	B-VP
O	217	220	act	act	VB	I-VP
O	221	223	in	in	IN	B-PP
B-Cancer	224	229	tumor	tumor	NN	B-NP
O	229	230	-	-	HYPH	B-NP
O	230	237	induced	induce	VBN	I-NP
O	238	250	angiogenesis	angiogenesis	NN	I-NP
O	251	253	by	by	IN	B-PP
O	254	261	binding	bind	VBG	B-VP
O	262	264	to	to	TO	B-PP
O	265	273	specific	specific	JJ	B-NP
O	274	283	receptors	receptor	NNS	I-NP
O	284	286	on	on	IN	B-PP
O	287	290	the	the	DT	B-NP
B-Cellular_component	291	298	surface	surface	NN	I-NP
O	299	301	of	of	IN	B-PP
B-Cell	302	313	endothelial	endothelial	JJ	B-NP
I-Cell	314	319	cells	cell	NNS	I-NP
O	319	320	.	.	.	O

O	321	324	One	One	CD	B-NP
O	325	329	such	such	JJ	I-NP
O	330	338	receptor	receptor	NN	I-NP
O	338	339	,	,	,	O
O	340	345	VEGFR	VEGFR	NN	B-NP
O	345	346	-	-	HYPH	B-NP
O	346	347	2	2	CD	I-NP
O	347	348	/	/	SYM	I-NP
O	348	351	KDR	KDR	NN	I-NP
O	351	352	,	,	,	O
O	353	358	plays	play	VBZ	B-VP
O	359	360	a	a	DT	B-NP
O	361	364	key	key	JJ	I-NP
O	365	369	role	role	NN	I-NP
O	370	372	in	in	IN	B-PP
O	373	377	VEGF	VEGF	NN	B-NP
O	377	378	-	-	HYPH	B-NP
O	378	385	induced	induce	VBN	I-NP
O	386	398	angiogenesis	angiogenesis	NN	I-NP
O	398	399	.	.	.	O

O	400	404	Here	Here	RB	B-ADVP
O	404	405	,	,	,	O
O	406	408	we	we	PRP	B-NP
O	409	418	expressed	express	VBD	B-VP
O	419	422	the	the	DT	B-NP
O	423	432	catalytic	catalytic	JJ	I-NP
O	433	439	domain	domain	NN	I-NP
O	440	442	of	of	IN	B-PP
O	443	448	VEGFR	VEGFR	NN	B-NP
O	448	449	-	-	HYPH	B-NP
O	449	450	2	2	CD	I-NP
O	451	453	as	as	IN	B-PP
O	454	455	a	a	DT	B-NP
O	456	463	soluble	soluble	JJ	I-NP
O	464	470	active	active	JJ	I-NP
O	471	477	kinase	kinase	NN	I-NP
O	478	483	using	use	VBG	B-VP
O	484	487	Bac	Bac	NN	B-NP
O	487	488	-	-	HYPH	B-ADJP
O	488	490	to	to	TO	B-PP
O	490	491	-	-	HYPH	B-NP
O	491	494	Bac	Bac	NN	I-NP
O	495	505	expression	expression	NN	I-NP
O	506	512	system	system	NN	I-NP
O	512	513	,	,	,	O
O	514	517	and	and	CC	O
O	518	530	investigated	investigate	VBN	B-VP
O	531	543	correlations	correlation	NNS	B-NP
O	544	551	between	between	IN	B-PP
O	552	557	VEGFR	VEGFR	NN	B-NP
O	557	558	-	-	HYPH	O
O	558	559	2	2	CD	B-NP
O	560	568	activity	activity	NN	I-NP
O	569	572	and	and	CC	O
O	573	579	enzyme	enzyme	NN	B-NP
O	580	593	concentration	concentration	NN	I-NP
O	593	594	,	,	,	O
O	595	598	ATP	ATP	NN	B-NP
O	599	612	concentration	concentration	NN	I-NP
O	612	613	,	,	,	O
O	614	623	substrate	substrate	NN	B-NP
O	624	637	concentration	concentration	NN	I-NP
O	638	641	and	and	CC	O
O	642	650	divalent	divalent	JJ	B-NP
O	651	657	cation	cation	NN	I-NP
O	658	662	type	type	NN	I-NP
O	662	663	.	.	.	O

O	664	666	We	We	PRP	B-NP
O	667	671	used	use	VBD	B-VP
O	672	677	these	these	DT	B-NP
O	678	682	data	datum	NNS	I-NP
O	683	685	to	to	TO	B-VP
O	686	695	establish	establish	VB	I-VP
O	696	697	a	a	DT	B-NP
O	698	708	convenient	convenient	JJ	I-NP
O	708	709	,	,	,	I-NP
O	710	719	effective	effective	JJ	I-NP
O	720	723	and	and	CC	I-NP
O	724	727	non	non	AFX	I-NP
O	727	728	-	-	HYPH	I-NP
O	728	739	radioactive	radioactive	JJ	I-NP
O	740	745	ELISA	ELISA	NN	I-NP
O	746	755	screening	screening	NN	I-NP
O	756	765	technique	technique	NN	I-NP
O	766	769	for	for	IN	B-PP
O	770	773	the	the	DT	B-NP
O	774	788	identification	identification	NN	I-NP
O	789	792	and	and	CC	I-NP
O	793	803	evaluation	evaluation	NN	I-NP
O	804	806	of	of	IN	B-PP
O	807	816	potential	potential	JJ	B-NP
O	817	827	inhibitors	inhibitor	NNS	I-NP
O	828	831	for	for	IN	B-PP
O	832	837	VEGFR	VEGFR	NN	B-NP
O	837	838	-	-	HYPH	O
O	838	839	2	2	CD	B-NP
O	840	846	kinase	kinase	NN	I-NP
O	846	847	.	.	.	O

O	848	850	We	We	PRP	B-NP
O	851	859	screened	screen	VBD	B-VP
O	860	863	200	200	CD	B-NP
O	864	867	RTK	RTK	NN	I-NP
O	868	874	target	target	NN	I-NP
O	874	875	-	-	HYPH	B-NP
O	875	880	based	base	VBN	I-NP
O	881	890	compounds	compound	NNS	I-NP
O	891	894	and	and	CC	O
O	895	905	identified	identify	VBD	B-VP
O	906	909	one	one	CD	B-NP
O	910	911	(	(	(	O
O	911	914	TKI	TKI	NN	B-NP
O	914	915	-	-	HYPH	B-NP
O	915	917	31	31	CD	I-NP
O	917	918	)	)	)	O
O	919	923	that	that	WDT	B-NP
O	924	932	potently	potently	RB	B-ADVP
O	933	942	inhibited	inhibit	VBD	B-VP
O	943	948	VEGFR	VEGFR	NN	B-NP
O	948	949	-	-	HYPH	B-NP
O	949	950	2	2	CD	I-NP
O	951	957	kinase	kinase	NN	I-NP
O	958	966	activity	activity	NN	I-NP
O	967	968	(	(	(	O
O	968	972	IC50	IC50	NN	B-NP
O	972	973	=	=	SYM	B-VP
O	973	974	0	0	CD	B-NP
O	974	975	.	.	SYM	I-NP
O	975	978	596	596	CD	I-NP
O	979	985	microM	microM	NN	I-NP
O	985	986	)	)	)	O
O	986	987	.	.	.	O

O	988	997	Treatment	Treatment	NN	B-NP
O	998	1000	of	of	IN	B-PP
B-Cell	1001	1007	NIH3T3	NIH3T3	NN	B-NP
I-Cell	1007	1008	/	/	SYM	I-NP
I-Cell	1008	1011	KDR	KDR	NN	I-NP
I-Cell	1012	1017	cells	cell	NNS	I-NP
O	1018	1022	with	with	IN	B-PP
O	1023	1026	TKI	TKI	NN	B-NP
O	1026	1027	-	-	HYPH	B-NP
O	1027	1029	31	31	CD	I-NP
O	1030	1037	blocked	block	VBD	B-VP
O	1038	1042	VEGF	VEGF	NN	B-NP
O	1042	1043	-	-	HYPH	B-NP
O	1043	1050	induced	induce	VBN	I-NP
O	1051	1066	phosphorylation	phosphorylation	NN	I-NP
O	1067	1069	of	of	IN	B-PP
O	1070	1073	KDR	KDR	NN	B-NP
O	1074	1076	in	in	IN	B-PP
O	1077	1078	a	a	DT	B-NP
O	1079	1083	dose	dose	NN	I-NP
O	1083	1084	-	-	HYPH	B-NP
O	1084	1093	dependent	dependent	JJ	I-NP
O	1094	1100	manner	manner	NN	I-NP
O	1100	1101	.	.	.	O

O	1102	1110	Moreover	Moreover	RB	B-ADVP
O	1110	1111	,	,	,	O
O	1112	1115	TKI	TKI	NN	B-NP
O	1115	1116	-	-	HYPH	O
O	1116	1118	31	31	CD	B-NP
O	1119	1123	dose	dose	NN	I-NP
O	1123	1124	-	-	HYPH	B-NP
O	1124	1135	dependently	dependently	RB	B-ADVP
O	1136	1146	suppressed	suppress	VBD	B-VP
B-Tissue	1147	1152	HUVEC	HUVEC	NN	B-NP
I-Tissue	1153	1157	tube	tube	NN	I-NP
O	1158	1167	formation	formation	NN	I-NP
O	1167	1168	.	.	.	O

O	1169	1173	Thus	Thus	RB	B-ADVP
O	1173	1174	,	,	,	O
O	1175	1177	we	we	PRP	B-NP
O	1178	1184	herein	herein	RB	B-ADVP
O	1185	1191	report	report	VBP	B-VP
O	1192	1193	a	a	DT	B-NP
O	1194	1199	novel	novel	JJ	I-NP
O	1199	1200	,	,	,	I-NP
O	1201	1210	efficient	efficient	JJ	I-NP
O	1211	1217	method	method	NN	I-NP
O	1218	1221	for	for	IN	B-PP
O	1222	1233	identifying	identify	VBG	B-VP
O	1234	1239	VEGFR	VEGFR	NN	B-NP
O	1239	1240	-	-	HYPH	B-NP
O	1240	1241	2	2	CD	I-NP
O	1242	1248	kinase	kinase	NN	I-NP
O	1249	1259	inhibitors	inhibitor	NNS	I-NP
O	1260	1263	and	and	CC	O
O	1264	1273	introduce	introduce	VB	B-VP
O	1274	1277	one	one	CD	B-NP
O	1277	1278	,	,	,	O
O	1279	1282	TKI	TKI	NN	B-NP
O	1282	1283	-	-	HYPH	B-NP
O	1283	1285	31	31	CD	I-NP
O	1285	1286	,	,	,	O
O	1287	1291	that	that	WDT	B-NP
O	1292	1295	may	may	MD	B-VP
O	1296	1301	prove	prove	VB	I-VP
O	1302	1304	to	to	TO	I-VP
O	1305	1307	be	be	VB	I-VP
O	1308	1309	a	a	DT	B-NP
O	1310	1316	useful	useful	JJ	I-NP
O	1317	1320	new	new	JJ	I-NP
O	1321	1333	angiogenesis	angiogenesis	NN	I-NP
O	1334	1343	inhibitor	inhibitor	NN	I-NP
O	1343	1344	.	.	.	O

